LifeScience Plus announced the approval of its revolutionary wound care products BloodSTOP® and BloodSTOP® iX for imports and sales in Thailand. The TFDA (Thailand Food And Drug Administration) approval unlocks the access to $1 billion medical device market. LifeScience Plus is currently working with its Thailand distributors, SDA Medical Co., Ltd, on training surgeons in BloodSTOP® and BloodSTOP® iX products use in various applications.

BloodSTOP® iX is a biocompatible, non-irritating, new generation patented hemostatic matrix. Using a proprietary formulation, natural sodium carboxymethyl cellulose is etherified to make a water-soluble, bioresorbable matrix. BloodSTOP® iX is designed for surgical and hospitals use, being highly biocompatible.  It can be used in internal surgery in markets and for patients taking anticoagulant medications that recognize the European Union CE certification* and has FDA market clearance in the US for surface wound hemostasis only. Applications include general surgery, ENT procedures, thoracic surgery, neurosurgery and many other surgical and post-surgical procedures.